Designed endocytosis-inducing proteins degrade targets and amplify signals
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
(KineTACs) have used this to target specific proteins for degradation by fusing modified native ligands to target binding proteins. Although powerful, these approaches can be limited by competition with native ligands and requirements for chemical modification that limit genetic encodability and can complicate manufacturing, and, more generally, there may be no native ligands that stimulate endocytosis through a given receptor. Here we describe computational design approaches for endocytosis-triggering binding proteins (EndoTags) that overcome these challenges. We present EndoTags for insulin-like growth factor 2 receptor (IGF2R) and asialoglycoprotein receptor (ASGPR), sortilin and transferrin receptors, and show that fusing these tags to soluble or transmembrane target protein binders leads to lysosomal trafficking and target degradation. As these receptors have different tissue distributions, the different EndoTags could enable targeting of degradation to different tissues. EndoTag fusion to a PD-L1 antibody considerably increases efficacy in a mouse tumour model compared to antibody alone. The modularity and genetic encodability of EndoTags enables AND gate control for higher-specificity targeted degradation, and the localized secretion of degraders from engineered cells. By promoting endocytosis, EndoTag fusion increases signalling through an engineered ligand-receptor system by nearly 100-fold. EndoTags have considerable therapeutic potential as targeted degradation inducers, signalling activators for endocytosis-dependent pathways, and cellular uptake inducers for targeted antibody-drug and antibody-RNA conjugates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 1×
“We began by investigating the ability of EndoTags to target and degrade EGFR, which is frequently overexpressed in cancers and has an important role in regulating cell proliferation 31 .”
Robust deep learning–based protein sequence design using ProteinMPNN
Dauparas, J., Anishchenko, I., Bennett, N., Bai, H., Ragotte, R. J., Milles, L. F., Wicky, B. I. M., Courbet, A., de Haas, R. J., Bethel, N., et al. (2022) · Science · doi:10.1126/science.add2187 · Cited by 2,210
Self-citationProtein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161 · cited 1×
“Here we describe computational design approaches for endocytosis-triggering binding proteins (EndoTags) that overcome these challenges.”
Robust deep learning based protein sequence design using ProteinMPNN
Dauparas, J., Anishchenko, I., Bennett, N., Bai, H., Ragotte, R. J., Milles, L. F., Wicky, B. I. M., Courbet, A., de Haas, R. J., Bethel, N., et al. (2022) · doi:10.1101/2022.06.03.494563 · Cited by 2,107
Self-citationPD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199 · cited 4×
“ASGPR is a liver-specific receptor that transports N -acetylgalactosamine (GalNAc)-labelled proteins into lysosomes for clearance 27 .”
InfluentialSelf-citationDe novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Cao, L., Goreshnik, I., Coventry, B., Case, J. B., Miller, L., Kozodoy, L., Chen, R. E., Carter, L., Walls, A. C., Park, Y.-J., et al. (2020) · Science · doi:10.1126/science.abd9909 · Cited by 742 · cited 2×
“We used the Rosetta RIFdock method 15,16 to design small proteins (minibinders) that bind to domain 6 and domain 11 (Extended Data Fig.”
Self-citationDesign of protein-binding proteins from the target structure alone
Cao, L., Coventry, B., Goreshnik, I., Huang, B., Sheffler, W., Park, J. S., Jude, K. M., Marković, I., Kadam, R. U., Verschueren, K. H. G., et al. (2022) · Nature · doi:10.1038/s41586-022-04654-9 · Cited by 577
Self-citationStructure of the human transferrin receptor-transferrin complex
Cheng, Y., Zak, O., Aisen, P., Harrison, S. C., & Walz, T. (2004) · Cell · doi:10.1016/s0092-8674(04)00130-8 · Cited by 571
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B., & Wells, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10008 · Cited by 551 · cited 3×
“Antibodies have been identified that stimulate endocytosis, but this can require considerable empirical screening for any target receptor 10,11 .”
De novo design of potent and selective mimics of IL-2 and IL-15
Silva, D.-A., Yu, S., Ulge, U. Y., Spangler, J. B., Jude, K. M., Labão-Almeida, C., Ali, L. R., Quijano-Rubio, A., Ruterbusch, M., Leung, I., et al. (2019) · Nature · doi:10.1038/s41586-018-0830-7 · Cited by 531 · cited 2×
“…proteases, but was blocked by chloroquine, which disrupts endosomal acidification, suggesting that EndoTag-enhanced signalling occurs in the endosome (inhibition of γ-secretase, which carries out the proteolytic cleavage needed to free the transcription factor, also blocked signalling) (Fig.”
Self-citationScaffolding protein functional sites using deep learning
Wang, J., Lisanza, S., Juergens, D., Tischer, D., Watson, J. L., Castro, K. M., Ragotte, R., Saragovi, A., Milles, L. F., Baek, M., et al. (2022) · Science · doi:10.1126/science.abn2100 · Cited by 487 · cited 2×
“3) on the basis of their binding modes to IGF2R, sampled the rigid-body orientation between the domain 11-and domain 6-binding elements to explore a range of induced receptor conformations, and connected the two chains were using RFInpainting 24 .”
Self-citationMassively parallel de novo protein design for targeted therapeutics
Chevalier, A., Silva, D.-A., Rocklin, G. J., Hicks, D. R., Vergara, R., Murapa, P., Bernard, S. M., Zhang, L., Lam, K.-H., Yao, G., et al. (2017) · Nature · doi:10.1038/nature23912 · Cited by 453 · cited 3×
“De novo protein design has the advantage of being able to target binders to specific sites of interest on a target 15–17 , and is thus well suited to designing protein binders that target receptor sites that do not overlap with those of native ligands.”
Self-citationEndosomes: A legitimate platform for the signaling train
Murphy, J. E., Padilla, B. E., Hasdemir, B., Cottrell, G. S., & Bunnett, N. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906541106 · Cited by 373
De novo design of a fluorescence-activating β-barrel
Dou, J., Vorobieva, A. A., Sheffler, W., Doyle, L. A., Park, H., Bick, M. J., Mao, B., Foight, G. W., Lee, M. Y., Gagnon, L. A., et al. (2018) · Nature · doi:10.1038/s41586-018-0509-0 · Cited by 351
Self-citationAntibody targeting of E3 ubiquitin ligases for receptor degradation
Marei, H., Tsai, W.-T. K., Kee, Y.-S., Ruiz, K., He, J., Cox, C., Sun, T., Penikalapati, S., Dwivedi, P., Choi, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05235-6 · Cited by 273
Pance, K., Gramespacher, J. A., Byrnes, J. R., Salangsang, F., Serrano, J.-A. C., Cotton, A. D., Steri, V., & Wells, J. A. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01456-2 · Cited by 265 · cited 2×
“Although powerful, these approaches have the limitations that native ligands can trigger off-target signalling 3,7 , their binding sites may be occupied by existing ligands 8 , and instability and—in some cases—the need for modification can complicate manufacturing 9 .”
Research works printed but not linked: 34
- Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021). · DOI · Paper page
- Sorkin, A. & von Zastrow, M. Endocytosis and signalling: intertwining molecular networks. Nat. Rev. Mol. Cell Biol. 10, 609–622 (2009). · DOI · Paper page
- Gao, H., Shi, W. & Freund, L. B. Mechanics of receptor-mediated endocytosis. Proc. Natl Acad. Sci. USA 102, 9469–9474 (2005). · DOI · Paper page
- Kaksonen, M. & Roux, A. Mechanisms of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 19, 313–326 (2018). · DOI · Paper page
- Harris, L. K. & Westwood, M. Biology and significance of signalling pathways activated by IGF-II. Growth Factors 30, 1–12 (2012). · DOI
- Ahn, G. et al. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras. Science 382, eadf6249 (2023). · DOI · Paper page
- Nykjaer, A. & Willnow, T. E. Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci. 35, 261–270 (2012). · DOI · Paper page
- Gammella, E., Buratti, P., Cairo, G. & Recalcati, S. The transferrin receptor: the cellular iron gate. Metallomics 9, 1367–1375 (2017). · DOI · Paper page
- Gustafsen, C. et al. Sortilin and SorLA display distinct roles in processing and trafficking of amyloid precursor protein. J. Neurosci. 33, 64–71 (2013). · DOI · Paper page
- Leloup, N. et al. Low pH-induced conformational change and dimerization of sortilin triggers endocytosed ligand release. Nat. Commun. 8, 1708 (2017). · DOI · Paper page
- Gatter, K. C., Brown, G., Trowbridge, I. S., Woolston, R. E. & Mason, D. Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 36, 539–545 (1983). · DOI · Paper page
- Sahtoe, D. D. et al. Transferrin receptor targeting by de novo sheet extension. Proc. Natl Acad. Sci. USA 118, e2021569118 (2021). · DOI · Paper page
- Sahtoe, D. D. et al. Reconfigurable asymmetric protein assemblies through implicit negative design. Science 375, eabj7662 (2022). · DOI · Paper page
- Wang, R., Qi, X., Schmiege, P., Coutavas, E. & Li, X. Marked structural rearrangement of mannose 6-phosphate/IGF2 receptor at different pH environments. Sci. Adv. 6, eaaz1466 (2020). · DOI
- Rennick, J. J., Johnston, A. P. R. & Parton, R. G. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat. Nanotechnol. 16, 266–276 (2021). · DOI · Paper page
- Cullen, P. J. & Steinberg, F. To degrade or not to degrade: mechanisms and significance of endocytic recycling. Nat. Rev. Mol. Cell Biol. 19, 679–696 (2018). · DOI · Paper page
- Zhang, H. et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. J. Am. Chem. Soc. 143, 16377–16382 (2021). · DOI · Paper page
- Paunovska, K., Loughrey, D. & Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 23, 265–280 (2022). · DOI · Paper page
- Brown, J., Jones, E. Y. & Forbes, B. E. Keeping IGF-II under control: Lessons from the IGF-II–IGF2R crystal structure. Trends Biochem. Sci 34, 612–619 (2009). · DOI
- Steiner, P. et al. Tumor growth inhibition with cetuximab and chemotherapy in non–small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin. Cancer Res. 13, 1540–1551 (2007). · DOI · Paper page
- Ryu, R. & Ward, K. E. Atezolizumab for the first-line treatment of non-small cell lung cancer (NSCLC): current status and future prospects. Front. Oncol. 8, 277 (2018). · DOI
- Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012). · DOI · Paper page
- Walker, L. S. K. & Sansom, D. M. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11, 852–863 (2011). · DOI · Paper page
- Yang, W. et al. Design of high affinity binders to convex protein target sites. Preprint at bioRxiv https://doi.org/10.1101/2024.05.01.592114 (2024). · DOI
- Piraner, D. I. et al. Engineered receptors for soluble cell-to-cell communication. Preprint at bioRxiv https://doi.org/10.1101/2024.09.17.613377 (2024). · doi:10.1101/2024.09.17.613377
- Elkon, K. & Casali, P. Nature and functions of autoantibodies. Nat. Clin. Pract. Rheumatol. 4, 491–498 (2008). · DOI · Paper page
- Akerström, B., Brodin, T., Reis, K. & Björck, L. Protein G: a powerful tool for binding and detection of monoclonal and polyclonal antibodies. J. Immunol. 135, 2589–2592 (1985). · doi:10.4049/jimmunol.135.4.2589
- Lajoie, M. J. et al. Designed protein logic to target cells with precise combinations of surface antigens. Science 369, 1637–1643 (2020). · DOI · Paper page
- Langan, R. A. et al. De novo design of bioactive protein switches. Nature 572, 205–210 (2019). · DOI · Paper page
- Yeh, A. H.-W. et al. De novo design of luciferases using deep learning. Nature 614, 774–780 (2023). · DOI · Paper page
- Debacker, A. J., Voutila, J., Catley, M., Blakey, D. & Habib, N. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol. Ther. 28, 1759–1771 (2020). · DOI · Paper page
- Quistgaard, E. M. et al. Revisiting the structure of the Vps10 domain of human sortilin and its interaction with neurotensin. Protein Sci. 23, 1291–1300 (2014). · DOI · Paper page
- Greisen, P. Jr et al. Computational design of N-linked glycans for high throughput epitope profiling. Protein Sci. 32, e4726 (2023). · DOI
- Zanghellini, A. et al. New algorithms and an in silico benchmark for computational enzyme design. Protein Sci. 15, 2785–2794 (2006). · DOI · Paper page
Cited by
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Self-citationDiffusing protein binders to intrinsically disordered proteins
Liu, C., Wu, K., Choi, H., Han, H. L., Zhang, X., Watson, J. L., Ahn, G., Zhang, J. Z., Shijo, S., Good, L. L., et al. (2025) · Nature · doi:10.1038/s41586-025-09248-9 · Cited by 79
Self-citationImproving diffusion-based protein backbone generation with global-geometry-aware latent encoding
(2025) · doi:10.1038/s42256-025-01059-x · Cited by 7
Metadata
- Authors
- Huang, B., Abedi, M., Ahn, G., Coventry, B., Sappington, I., Tang, C., Wang, R., Schlichthaerle, T., Zhang, J. Z., Wang, Y., Goreshnik, I., Chiu, C. W., Chazin-Gray, A., Chan, S., Gerben, S., Murray, A., Wang, S., O’Neill, J., Yi, L., Yeh, R., Misquith, A., Wolf, A., Tomasovic, L. M., Piraner, D. I., Duran Gonzalez, M. J., Bennett, N. R., Venkatesh, P., Ahlrichs, M., Dobbins, C., Yang, W., Wang, X., Sahtoe, D. D., Vafeados, D., Mout, R., Shivaei, S., Cao, L., Carter, L., Stewart, L., Spangler, J. B., Roybal, K. T., Greisen, P. J., Li, X., Bernardes, G. J. L., Bertozzi, C. R., & Baker, D.
- Venue
- Nature
- Published
- 2024-09-25
- Volume
- 638
- Issue
- 8051
- Pages
- 796-804
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4402827225
- Cited by
- 146
- References
- 18
- FWCI
- 16.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.